Dr David Lewis, OzUK Director, tackles MDI stability at DDL 2021

Dr. David Lewis is a founding Director of Oz-UK Limited. He holds a B.Sc. in Physics (1989) and M.Sc. and Ph.D. in Aerosol Science (1990 & 1994), from Essex University, England.

David joined the Centre for Drug Formulation Studies at Bath University, England, in May 1996 to lead a start-up HFA programme sponsored by Chiesi Farmaceutici. The resultant successful development of HFA solution formulations lead to a rapid expansion of his group which transferred to Vectura in 1999 as a result of CDFS spin-out by the University of Bath. David joined Chiesi Limited in 2008 and established the UK Research Centre in Chippenham, UK which opened in July 2009. In 2015, David Co-founded Oz-UK Limited; an Australian-UK based company developing inhaler technologies and formulations for clients across the world.

David has authored/coauthored over 175 research publications within the fields of pharmaceutics, analytical chemistry, and aerosol science, and is co-inventor of over 30 patents relating to pressurized metered dose inhaler formulations and devices. These inventions led to proprietary technology which has seen formulations of beclomethasone dipropionate, budesonide, formoterol and a beclomethasone dipropionate-formoterol combination becoming commercialized in several European countries.